Kyushu University Academic Staff Educational and Research Activities Database
List of Presentations
Shingo Baba Last modified date:2023.11.27

Professor / Department of Radiology / Department of Health Sciences / Faculty of Medical Sciences


Presentations
1. Usefulness of MTV measurement of FDG-PET images of malignant lymphoma using machine learning model.
2. Usefulness of MTV measurement of FDG-PET images of malignant lymphoma using machine learning model .
3. Yasuhiro Maruoka, Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Masayuki Sasaki, Kousei Ishigami, Prognostic value of FDG-PET residual metabolic activity after initial 131I therapy for differentiated thyroid carcinoma with bone metastasis, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2022, 2022.06.
4. Yoshiyuki Kitamura, Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Takeo Fujino, Masayuki Sasaki, Kousei Ishigami, Usefulness of FDG-PET/CT for diagnosis of myocardial rejection after heart transplantation, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2022, 2022.06.
5. Establishment of automated tumor segmentation of whole-body FDG-PET using 3D U-net.
6. Establishment of automated tumor segmentation of whole-body FDG-PET using 3D U-net.
7. Comparison of CE-CT and scintigraphy in salivary gland dysfunction after repeated I-131 therapy .
8. Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Kousei Ishigami, Role of 18F-FDG PET/CT as a predictor of eradication of Helicobacter pylori in the patients with early-stage gastric B cell lymphoma, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2021, 2021.06, [URL].
9. Relationship between the visualization of the lesion and uptake time of 131NaI.
10. Takuro Isoda, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Akihiro Nishie, Kousei Ishigami, 131I / 18FDG Flip-Flop Phenomenon in the Bone Metastasis from Differentiated Thyroid Cancer, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2020, 2020.07, Objectives: Radioiodine therapy is used to treat distant metastases from thyroid cancer. A reverse relationship between iodine and FDG accumulation is found in thyroid cancer lesions, the so-called “flip-flop” phenomenon. The aim of this study was to assess the relationship between iodine and FDG uptake in bone metastasis lesions from thyroid cancer.Methods: The cases of 20 patients who underwent radioiodine therapy for bone metastasis were studied retrospectively (age, 27-74 yrs; median, 62 yrs; males : females, 6 : 14). Iodine uptake was evaluated visually and the lesions showing iodine uptake more than background were determined as positive. FDG uptake was assessed using SUVmax. We compared FDG uptake between the lesions with (n=19) and without (n=88) iodine uptake in bone metastasis.Results: The bone metastasis lesions without iodine showed significantly higher FDG uptake than those with iodine uptake (p 5). Enormously high degree of FDG uptake (SUVmax>10) was rare in the lesions with iodine uptake, while it was common in those without iodine uptake..
11. Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Ryo Somehara, Akio Hiwatashi, Saiji Ohga, Nobuhiro Hata, Hiroshi Honda, Comparison of visual and semiquantitativeanalysis of C-11 Methionine PET/CT for the differentiation of recurrent brain tumors from radiation necrosis after radiotherapy, Society of Nuclear Medicine and Molecular Imaging ,Annual Meeting 2019, 2019.07, Background
C-11Methionine positron emission tomography has reported to be useful to distinguish brain tumor recurrence from radiation necrosis. We undertook this study to directly compare visual and semiquantitative analysis for the evaluation of recurrence in brain tumors.
Method
Thirty-nine patients with a history of treated brain tumors (32 primary brain tumor and 7 metastatic tumor) referred for evaluation of recurrent disease were initially included in the study. There were 24 males and 15 females (mean age: 39.1. ± 15.4 years; range: 15 to 69 years). All patients are suspected recurrence, persistence, or necrotic post-therapeutic changes and underwent the MET PET/CT study. Visual image interpretation was performed independently by 2 PET physicians using the fused PET/CT images. Images were also analyzed semiquantitatively using ratio of SUVmax of tumor and normal contralateral white matter (T/Nw) and grey matter (T/Ng). Imaging results were compared with histopathology on tumor excision or biopsy in 12 patients and with clinical follow-up in 27 patients.
Results
The final diagnosis was tumor recurrence in 28 patients and no recurrence/stable disease in 11 patients. Visual analyses were positive in 25 (64.1%) and negative in 9 (35.9%). The sensitivity, specificity and accuracy were 82.1%, 81.8% and 82.1% respectively. For the semiquantitative analysis, positive cases were seen in 26 (66.7%) (TNw) and 25 (64.1%) (TNg). The sensitivity, specificity and accuracy were [89.3(TNw); 85.7(TNg)], [90.9(TNw); 90.9(TNg)] and [89.7(TNw); 87.2(TNg)] respectively. Highest AUC of 0.93 was seen in TNw using the cut-off value of 1.95. There was no statistically significant differences among three methods.
Conclusion
Although, it was a slight difference, diagnostic performance using semiquantitative analysis using T/Nw was the best among the three method used in this study. MET-PET/CT was a useful technique to differentiate post-therapeutic changes from tumor presence in treated patients with brain tumor in whom diagnosis was nonconclusive.
.
12. Assessment of the effect of urinary excretion rate of 18F-Sodium fluoride on the SUV of NaF PET/CT.
13. Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Clinical Impact of  radiolabeled amino acid PET for the diagnosis of cerebral gliomas, THE 13TH ASIA OCEANIA CONGRESS OF NUCLEAR MEDICINE AND BIOLOGY, 2019.05, BACKGROUND:
Magnetic resonance imaging (MRI) is the investigation of choice for diagnosing cerebral glioma, but its capacity to differentiate tumor tissue from non-specific tissue changes is limited. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a molecular imaging technique, which provides information on the metabolic behavior of the tumor. However, FDG-PET often leads to several controversies in making clinical decisions due to their high uptake of normal surrounding tissues, and pose difficulty in delineating treatment-induced necrosis, edema, inflammation, and pseudoprogression. Thus, it is imperative to find new approach to demarcate normal and tumor tissues. PET using radiolabeled amino acids is a promising technique and it increases diagnostic accuracy for brain tumor.
PURPOSE: We have provided some cases and literature of 11C methionine-PET (MET-PET) and other amino acid PET for gliomas, along with prognostic and diagnostic significance.
METHODS:
Review based on the authors' own research results and a selective literature review
RESULTS:
The use of radiolabeled amino acids allows better delineation of tumor margins and improves targeting of biopsy and radiotherapy, and planning surgery. In addition, amino acid imaging appears useful in distinguishing tumor recurrence from non-specific post-therapeutic necrosis, in predicting prognosis in low grade gliomas, and in monitoring metabolic response during treatment.
CONCLUSION:
Amino acid PET including MET-PET can lead to a better understanding of the existing controversies and can enhance our knowledge for future treatment of GBM patients based on their tumor gene signatures to achieve better prognosis and treatment outcome..
14. Quantitative parameters and metabolic heterogeneity of FDG-PET in oropharyngeal cancer..
15. Effect of spatial resolution on the PET Radiomics parameters of malignant tumors.
16. Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Ryo Somehara , Keiichiro Tahara, Akio Hiwatashi, Saiji Ohga, Koji Yshimoto, Hiroshi Honda, Comparison of F-18 FDG and C-11 Methionine PET/CT for the differentiation of recurrent brain tumors from radiation necrosis after radiotherapy, Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2018.06, Background
C-11Methionine positron emission tomography has reported to be useful to distinguish brain tumor recurrence from radiation necrosis. We undertook this study to directly compare F-18 flurodeoxyglucose (FDG) PET and C-11 methionine (MET) PET for the evaluation of recurrence in brain tumors.
Method
Thirty-seven patients with a history of treated brain tumors (31 primary brain tumor and 6 metastatic tumor) referred for evaluation of recurrent disease were initially included in the study. There were 22 males and 15 females (mean age: 38.7 ± 14.4 years; range: 15 to 65 years). All patients underwent the MET and FDG study within 2 weeks. Visual image interpretation was performed independently by 2 PET physicians for each tracer using the fused PET/CT images. Images were analyzed semiquantitatively using tumor to normal contralateral cortex ratios (T/N). Imaging results were compared with histopathology on tumor excision or biopsy in 10 patients and with clinical follow-up in 27 patients.
Results
The final diagnosis was tumor recurrence in 27 patients and no recurrence/stable disease in 10 patients. On FDG, findings in 23/37 (62.2%) were suggestive of recurrent tumors. On MET, findings in 28/37 (75.7%) cases were suggestive of recurrent tumors. Spatially separated secondary lesions were clearly delineated in 4 cases, 3 were glioblastoma multiforme (GBM) and 1 were anaplastic astrocytoma. Two of the secondary lesions were missed on FDG PET. Using a cutoff for T/N ratio on FDG of >0.90 to differentiate recurrence from no recurrence, sensitivity of FDG was 74.1%, whereas specificity was 70.0%. Area under the curve was 0.86. Using a cutoff for T/N ratio of >2.1 to differentiate recurrence from no recurrence, sensitivity of MET was 92.6%, whereas specificity was 80.0%. Area under the curve was 0.95.
Conclusion
Semiquantitative analysis of MET can provide more informative values than FDG to aid in the differentiation of tumor recurrence from radiation necrosis.
.
17. Takuro Isoda, Shingo Baba, Yoshiyuki Kitamura, Ryo Somehara , Keiichiro Tahara,Taiki Higo, Takeo Fujino, Masayuki Sasaki, Hiroshi Honda, FDG-PET of drive line infection and non-pathological uptake in or around a ventricular assist device, Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2018.06.
18. Yasuhiro Maruoka, Shingo Baba, Michinobu Nagao, Takuro Isoda, Kitamura Yoshiyuki, Keiichiro Tahara, Akihiro Nishie, Satoshi Kawanami, Abe Kohtaro, Kazuya Hosokawa, Masayuki Sasaki, Hiroshi Honda, Evaluation of Balloon Pulmonary Angioplasty Response for Chronic Thromboembolic Pulmonary Hypertension Using Fractal Analysis of 99mTc-MAA SPECT, 第56回日本核医学会学術総会, 2016.11.
19. Takuro Isoda, Shingo Baba, Yasuhiro Maruoka, Kitamura Yoshiyuki, Keiichiro Tahara, Masayuki Sasaki, Hiroshi Honda, Use of recombinant human thyroid-stimulating hormone (rhTSH) reduces the damage to salivary glands after radioiodine therapy for thyroid cancer, 63th Annual Meeting, Society of Nuclear Medicine, 2016.06.
20. Kitamura Yoshiyuki, Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Keiichiro Tahara, Masayuki Sasaki, Akihiro Nishie, Hiroshi Honda, Relationship of the I-123 Metaiodobenzylguanidine (MIBG) Uptake and Early Relapse of Neuroblastoma Using Semi-quantitative Analysis of SPECT/CT., 63th Annual Meeting, Society of Nuclear Medicine, 2016.06.
21. Yasuhiro Maruoka, Shingo Baba, Michinobu Nagao, Takuro Isoda, Kitamura Yoshiyuki, Keiichiro Tahara, Akihiro Nishie, Satoshi Kawanami, Abe Kohtaro, Kazuya Hosokawa, Masayuki Sasaki, Hiroshi Honda, Evaluation of Balloon Pulmonary Angioplasty Response for Chronic Thromboembolic Pulmonary Hypertension Using Fractal Analysis of 99mTc-MAA SPECT, 63th Annual Meeting, Society of Nuclear Medicine, 2016.06.
22. Shingo Baba, Yuji Watanabe, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, Keiichiro Tahara, Koji Sagiyama, Ryotaro Kamei, Hiroshi Honda, Evaluation of the novel method for the measurement of brain amyloid burden using PET/MRI, 第55回日本核医学会学術総会, 2015.10.
23. Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, Koji Sagiyama, Ryotaro Kamei, Yuji Watanabe, Hiroshi Honda, Evaluation of cortical uptake of amyloid PET tracer with hybrid PET/MRI; comparison with PET/CT, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06.
24. Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, KojI Kato, Masayuki Sasaki, Hiroshi Honda, Usefulness of FDG-PET/CT in the diagnosis of acute transformation of Adult T-cell Lymphoma, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06.
25. TAKURO ISODA, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Use of recombinant human thyroid-stimulating hormone (rhTSH) reduces the damage to salivary glands after radioiodine therapy for thyroid cancer, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06.
26. Akifumi Yamada, Shingo Baba, TAKURO ISODA, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Effective synthesis of Pittsburg Compound B (11C-PIB) for clinical application by on-column 11C-methylation, 62th Annual Meeting, Society of Nuclear Medicine, 2015.06.
27. TAKURO ISODA, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Impact of the patient age on flip-flop phenomenon in lung metastasis from thyroid cancer, 27th European Congress of Radiology, 2015.05.
28. Yasuhiro Maruoka, Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Relationship between effectiveness of I-131 therapy and 18F-FDG accumulation in differentiated thyroid carcinoma patients with lung metastasis., 61th Annual Meeting, Society of Nuclear Medicine, 2014.06.
29. Yoshiyuki Kitamura, Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Masayuki Sasaki, Hiroshi Honda, Comparison between lacrimal gland tumors of IgG4-related disease and MALT lymphoma at FDG PET/CT., 61th Annual Meeting, Society of Nuclear Medicine, 2014.06.
30. Yoshiyuki Kitamura, Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Masayuki Sasaki, Hiroshi Honda, Efficiency of the respiratory gating 18F-FDG PET/CT at lung adenocarcinoma: Comparison between the amplitude gating method and the phase gating method., 61th Annual Meeting, Society of Nuclear Medicine, 2014.06.
31. Takuro Isoda, Shingo Baba, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Evaluation of Diagnostic Performance of a Computer-Aided Diagnostic System, BONENAVI, on bone scintigraphy images, 61th Annual Meeting, Society of Nuclear Medicine, 2014.06.
32. Shingo Baba, Takuro Isoda, Yasuhiro Maruoka, Yoshiyuki Kitamura, Masayuki Sasaki, Hiroshi Honda, Usefulness of myocardial 123I-MIBG-SPECT for the differential diagnosis of Parkinson's syndrome, 61th Annual Meeting, Society of Nuclear Medicine, 2014.06.
33. Shingo Baba, Koichiro Abe, Takuro Isoda, Yasuhiro Maruoka, Masayuki Sasaki, Hiroshi Honda, Variability of size-collected pretreatment FDG uptake predicts prognosis of patients with diffuse large cell lymphoma., 59th Annual Meeting, Society of Nuclear Medicine, 2012.06, Purpose: To evaluate the usefulness of recovery-collected SUVs in the clinical diagnosis of malignant lymphoma patients.
Materials and Methods: Previously reported recovery-collection using simple table look-up method was used in this study. Recovery coefficient was estimated using size and signal-background ratio by phantom experiment. Fifty three patients of malignant lymphoma (DLBCL; 37, FL; 16) were subjected to FDG-PET/CT for initial staging. Recovery-collected SUVs (SUVcor) were calculated and average±SD, coefficient of variation (CV) of SUVcor were compared with those of conventional SUV within the patient and between the groups divided by histology and prognosis.
Result: Average±SD of SUVmax, SUVcor were higher in DLBCL (14.5±9.1, 18.6±9.6) than in FL(8.5±2.6, 11.7±3.24)( pConclusion: Uptakes of FDG free from partial-volume effect can be measured correctly with this method. Variability of pretreatment SUVs with size-collection is one of the independent predictor of the prognosis of patient with DLBCL.
.
34. ariability of size-collected SUV evaluated by FDG-PET/CT predicts prognosis of patients with diffuse large cell lymphoma..
35. Impact of PET/CT on clinical oncology; for the evaluation of treatment response and prospection :
malignant lymphoma.
36. , [URL].
37. The 18F-FAZA /FDG uptake ratio: Potential Index of tumor hypoxia?.